FDA Approves Belimumab Autoinjector for Pediatric Systemic Lupus Erythematosus
By Lori Solomon HealthDay Reporter
WEDNESDAY, May 22, 2024 -- The U.S. Food and Drug Administration has approved a 200-mg subcutaneous route of administration of Benlysta (belimumab) for patients 5 years of age and older with active systemic lupus erythematosus (SLE) who are receiving standard therapy.
The B-lymphocyte stimulator-specific inhibiting monoclonal antibody was previously approved for children aged 5 years and older via intravenous administration by health care professionals. With this approval, a child's health care provider can determine if at-home administration is appropriate, and if so, the patient's caregiver can administer the medicine at home via an autoinjector once per week for children who weigh ≥40 kg or once every two weeks for children who weigh 15 kg to <40 kg.
In adult trials, the most common serious adverse reactions were serious infections, some of which were fatal. The most common adverse reactions (≥5 percent) were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, and injection-site reactions. In clinical trials with SLE pediatric patients (aged 5 years and older) and adult patients with lupus nephritis, reported adverse reactions were consistent with those observed in adult SLE trials.
"Lupus tends to be more aggressive and affect children more severely than adults, with those diagnosed in childhood having higher rates of organ damage," Mary T. Crimmings, interim CEO at the Lupus Foundation of America, said in a statement. "Going to the doctor’s office once every four weeks can be a logistical hurdle for some children and their caregivers, so having the option to administer Benlysta in the comfort of their home provides much-needed flexibility."
Approval of Benlysta was granted to GlaxoSmithKline.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2024
Read this next
Pericarditis Recurrence Occurs in About 20 Percent of Patients With Lupus
TUESDAY, March 4, 2025 -- For patients with systemic lupus erythematosus (SLE) and pericarditis, recurrence of pericarditis occurs in more than 20 percent of patients and...
Anifrolumab Tied to Less Organ Damage for Patients With Lupus
THURSDAY, Feb. 20, 2025 -- For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks...
Air Pollutant Exposure Linked to Increased Risk for Incident Lupus
WEDNESDAY, July 10, 2024 -- Air pollutant exposure is associated with an increased likelihood of developing incident systemic lupus erythematosus (SLE), according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.